UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases BridgeBio Pharma, Inc.; UC San Francisco Palo Alto, California, UNITED STATES
SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.
“The BridgeBio team is developing close relationships with our investigators at UCSF with the mission of bringing potential therapies into the clinic quickly, where they have the opportunity to help patients in need,” said Barry Selick, Ph.D., UCSF vice chancellor for business development, innovation and partnerships and director of the Office of Innovation Ventures. “We are excited about this partnership and the opportunities it may create for the development of new medicines.”